The Insight Partners Latest Research for Report “Chronic Cough Market Forecast to 2027″ Focuses COVID-19 Impact and Global Analysis by Drug Class (Antihistamines, Corticosteroids, Decongestants, Combination Drug, Antibiotics, Acid Blockers, and Other Drug Class); Route of Administration (Oral, Injections, Inhalation, Other and Route of Administration); Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) and Geography
Chronic Cough Market Global Analysis and Forecast by Drug Class, Route of Administration, and Distribution Channel the global chronic cough market is expected to reach US$ 9,854.8 million by 2027 from US$ 5,430.0 million in 2019; it is estimated to grow at a CAGR of 7.8% from 2020 to 2027. The report highlights the trends prevalent in the global chronic cough market, and the drivers and deterrents pertaining to its growth.
Download PDF Sample Copy at:
Essential points covered in Global Chronic Cough Market Research are:-
- What will the market size and the growth rate be in 2028?
- What are the key factors driving the global market?
- What are the key market trends impacting the growth of the global market?
- What are the challenges to market growth?
- Who are the key vendors in the global market?
- What are the market opportunities and threats faced by the vendors in the global market?
- Trending factors influencing the market shares of the Americas, APAC, and EMEA.
- What are the key outcomes of the five forces analysis of the global market
Segment – By Drug Class
Based on drug class, the chronic cough market is segmented into antihistamines, cortico steroids, decongestants, combination drug, antibiotics, acid blockers, and others drug class. The combination drug segment held the largest share of the market in 2019 and the same segment is anticipated to register the highest CAGR in the market during the forecast period. The growth of the market through combination drug segments is estimated to grow due to enhanced sales of combination drugs over the counter and the use of combination drugs targets more symptoms in a single use.
Have a Call with Analyst:
Based on rout of administration, the chronic cough market is segmented into oral, injections, inhalation, and other route of administration. The oral segment held the largest share of the market in 2019. However, the inhalation segment is estimated to register the highest CAGR in the market during the forecast period.
Top Players Analysis:
- Novartis AG
- Teva Pharmaceutical Industries Ltd
- Glaxo Smith Klineplc.
- Bayer AG
- Mylan N.V.
- Amneal Pharmaceuticals, Inc.
- Cipla Inc.
- Reckitt Benckiser Group plc.
- Sun Pharmaceutical Industries Ltd
- AurobindoPharma Ltd
The growth of the market is attributed to the factors such as increase in rising incidences of chronic cough and growing product developments to treat chronic cough. On the other hand, product recall is the major factor likely to restraint the market growth during the forecast period.
Buy Report at:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi